Product Description
Mechanisms of Action: PDK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Colombia | India | Peru | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: University of Florida
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Insulin Resistance
Phase 3: Acidosis, Lactic|Pyruvate Dehydrogenase Complex Deficiency Disease
Phase 2: Head and Neck Cancer|Healthy Volunteers|Non-Small-Cell Lung Cancer|Breast Cancer|Glioblastoma|MELAS Syndrome|Squamous Cell Carcinoma|Acidosis, Lactic|Glioma|Multiple Myeloma
Phase 1: Glioblastoma|MELAS Syndrome|Brain Cancer|Protein Deficiency|Liver Cancer|Potassium Deficiency|Acidosis, Lactic|Evans Syndrome|Lung Cancer|Breast Cancer|Tumor Lysis Syndrome|Healthy Volunteers|Brain Death|Brain Injuries|Hypertension, Pulmonary|Hyperglycemia|Familial Primary Pulmonary Hypertension|Hypoglycemia|Type 1 Diabetes|Pyruvate Dehydrogenase Complex Deficiency Disease|Deficiency Diseases|Head and Neck Cancer|Mitochondrial Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HSC-MS-24-0756 | N/A |
Not yet recruiting |
Generalized anxiety disorder |
2027-06-30 |
|
DCA | P2 |
Not yet recruiting |
Glioblastoma |
2026-12-30 |
|
ACTRN12623001164684 | N/A |
Recruiting |
Nose Cancer |
2026-10-30 |
|
NCT05317455 | P1 |
Not yet recruiting |
Type 1 Diabetes|Hypoglycemia |
2025-10-01 |